
  
    
      
        Background_NNP
        Acute_NNP graft_NN versus_CC host_NN disease_NN (_( A-GVHD_NNP )_) is_VBZ a_DT
        significant_JJ cause_NN of_IN morbidity_NN and_CC mortality_NN following_VBG
        allogeneic_JJ bone_NN marrow_NN transplantation_NN (_( BMT_NNP )_) ._. It_PRP frequently_RB
        involves_VBZ skin_NN ,_, intestinal_NN tract_NN ,_, and_CC liver_NN ._. The_DT incidence_NN
        of_IN A-GVHD_NNP after_IN allogeneic_JJ BMT_NNP ranges_NNS from_IN 30_CD %_NN to_TO 60_CD %_NN with_IN
        skin_NN as_IN the_DT most_RBS commonly_RB affected_VBN organ_NN often_RB accompanied_VBN
        by_IN intestinal_NN and_CC /_NN or_CC liver_NN involvement_NN [_NN 1_CD 2_CD 3_CD 4_CD ]_NN ._.
        Intestinal_NNP A-GVHD_NNP may_MD manifest_JJ as_IN abdominal_NN cramps_NNS ,_, ileus_JJ ,_,
        profuse_NN diarrhea_NN ,_, and_CC sometimes_RB bleeding_VBG ._. However_RB ,_, these_DT
        symptoms_NNS are_VBP not_RB specific_JJ and_CC include_VBP broad_JJ differential_NN
        diagnoses_NNS such_JJ as_IN chemotherapy_NN effect_NN ,_, radiation_NN therapy_NN
        effect_NN ,_, infections_NNS ,_, and_CC side_NN effects_NNS of_IN other_JJ drugs_NNS [_NN 5_CD 6_CD 7_CD
        8_CD 9_CD ]_NN ._. Furthermore_RB ,_, the_DT histomorphological_JJ features_NNS of_IN
        these_DT conditions_NNS overlap_VBP significantly_RB with_IN A-GVHD_NNP ._. Due_JJ to_TO
        this_DT ,_, interpretation_NN of_IN colonic_JJ biopsies_NNS for_IN intestinal_NN
        A-GVHD_NNP may_MD be_VB a_DT major_JJ diagnostic_JJ challenge_NN especially_RB for_IN
        those_DT not_RB conversant_NN with_IN these_DT findings_NNS [_NN 10_CD ]_NN ._. Only_RB a_DT
        few_JJ studies_NNS have_VBP statistically_RB evaluated_VBN the_DT diagnostic_JJ
        significance_NN of_IN some_DT histopathological_JJ features_NNS [_NN 6_CD ]_NN ._.
        A-GVHD_NNP is_VBZ treated_VBN with_IN immunosuppression_NN which_WDT may_MD worsen_VB
        an_DT underlying_VBG infective_JJ condition_NN ._. Thus_RB it_PRP is_VBZ extremely_RB
        important_JJ to_TO diagnose_NN these_DT conditions_NNS correctly_RB for_IN proper_JJ
        management_NN ._.
        In_IN addition_NN to_TO other_JJ histopathological_JJ features_NNS
        described_VBD in_IN association_NN with_IN A-GVHD_NNP ,_, significance_NN of_IN
        apoptosis_NNS ,_, crypt_NN abscess_NNS ,_, and_CC crypt_NN loss_NN has_VBZ been_VBN
        emphasized_VBN [_NN 4_CD 11_CD 12_CD 13_CD 14_CD 15_CD ]_NN ._. However_RB ,_, the_DT distribution_NN
        pattern_NN of_IN apoptosis_NNS in_IN colonic_JJ mucosa_NN in_IN A-GVHD_NNP has_VBZ not_RB
        been_VBN methodically_RB evaluated_VBN ._. Similarly_RB the_DT term_NN '_'' crypt_NN
        abscesses_NNS '_POS has_VBZ been_VBN used_VBN previously_RB in_IN A-GVHD_NNP ,_, although_IN it_PRP
        appears_VBZ to_TO be_VB a_DT misnomer_NN as_IN discussed_VBN later_RB ._. This_DT may_MD lead_VB
        to_TO confusion_NN with_IN '_POS crypt_NN abscess_NNS '_POS of_IN inflammatory_JJ bowel_NN
        disease_NN ._. '_POS Crypt_NNP abscess_NNS '_POS and_CC '_POS cryptitis_NNS '_POS associated_VBN with_IN
        inflammatory_JJ bowel_NN diseases_NNS ,_, not_RB been_VBN evaluated_VBN in_IN
        intestinal_NN A-GVHD_NNP previously_RB ,_, were_VBD specifically_RB studied_VBN to_TO
        confirm_VB the_DT misnomer_NN status_NN ._.
        We_PRP retrospectively_RB analyzed_VBD various_JJ histomorphological_JJ
        features_NNS in_IN 44_CD colon_NN biopsies_NNS from_IN BMT_NNP patients_NNS with_IN
        cutaneous_JJ A-GVHD_NNP and_CC diarrhea_NN ._. These_DT were_VBD compared_VBN with_IN 48_CD
        colon_NN biopsies_NNS from_IN negative_JJ control_NN groups_NNS ._. The_DT goal_NN of_IN
        this_DT study_NN was_VBD to_TO systematically_RB evaluate_VB the_DT diagnostic_JJ
        reliability_NN of_IN various_JJ histomorphological_JJ features_NNS with_IN
        reference_NN to_TO intestinal_NN A-GVHD_NNP ._.
      
      
        Methods_NNP
        
          Group_NNP Definitions_NNP
          
            Group_NNP A_DT
            Consisted_NNP of_IN 44_CD patients_NNS (_( 25_CD males_NNS and_CC 19_CD females_NNS ,_,
            19_CD to_TO 59_CD years_NNS of_IN age_NN ,_, mean_VB 41_CD ._. 6_CD years_NNS )_) with_IN diarrhea_NN
            and_CC biopsy_NN proven_VBN cutaneous_JJ A-GVHD_NNP ._. In_IN this_DT group_NN ,_,
            intestinal_NN A-GVHD_NNP was_VBD strongly_RB favored_VBN ,_, in_IN the_DT absence_NN
            of_IN other_JJ etiologies_NNS such_JJ as_IN CMV_NNP colitis_NNS and_CC NSAIDs_NNP [_NN 2_CD
            4_CD 7_CD 9_CD 12_CD 16_CD 17_CD ]_NN ._. CMV_NNP colitis_NNS cases_NNS were_VBD excluded_VBN
            morphologically_RB based_VBN on_IN the_DT presence_NN of_IN CMV_NNP cytopathic_JJ
            effect_NN or_CC CMV_NNP immunohistochemistry_NN ._. The_DT cases_NNS with_IN
            suspicious_JJ features_NNS such_JJ as_IN ill_RB defined_VBN cytopathic_JJ
            changes_NNS and_CC ischemic_JJ features_NNS were_VBD also_RB automatically_RB
            excluded_VBN without_IN performing_VBG CMV_NNP immunohistochemistry_NN to_TO
            avoid_VB possibility_NN of_IN inclusion_NN of_IN cases_NNS with_IN CMV_NNP ._. These_DT
            44_CD colon_NN biopsies_NNS were_VBD performed_VBN 21_CD to_TO 100_CD day_NN post-_NN BMT_NNP
            (_( median_JJ 35_CD days_NNS )_) prior_RB to_TO the_DT commencement_NN of_IN treatment_NN
            for_IN A-GVHD_NNP and_CC within_IN 15_CD days_NNS of_IN A-GVHD_NNP positive_JJ skin_NN
            biopsy_NN for_IN investigating_VBG their_PRP$ diarrhea_NN ._.
            The_DT underlying_VBG indications_NNS for_IN BMT_NNP in_IN these_DT 44_CD cases_NNS
            in_IN group_NN A_DT are_VBP shown_VBN in_IN Table_NNP 1_CD ._. The_DT distribution_NN of_IN
            cases_NNS with_IN reference_NN to_TO the_DT grading_VBG of_IN cutaneous_JJ A-GVHD_NNP
            included_VBD ,_, 20_CD cases_NNS with_IN grade_NN I_PRP ,_, 13_CD with_IN grade_NN II_NNP ,_, 5_CD
            with_IN grade_NN III_NNP ,_, and_CC 6_CD with_IN grade_NN IV_NNP ._. Published_VBN clinical_JJ
            and_CC histological_JJ criteria_NNS were_VBD used_VBN to_TO define_VB cutaneous_JJ
            and_CC intestinal_NN A-GVHD_NNP [_NN 12_CD 13_CD 14_CD 18_CD 19_CD ]_NN ._. Grading_NNP of_IN
            A-GVHD_NNP was_VBD not_RB attempted_VBN in_IN colon_NN biopsies_NNS ._.
          
          
            Group_NNP B_NNP
            (_( negative_JJ control_NN I_PRP )_) :_: Included_VBN 27_CD patients_NNS (_( 13_CD males_NNS
            and_CC 14_CD females_NNS ,_, 20_CD to_TO 77_CD years_NNS of_IN age_NN ,_, mean_VB 51_CD ._. 5_LS years_NNS )_)
            without_IN immunodeficiency_NN ,_, BMT_NNP ,_, or_CC any_DT other_JJ
            transplantation_NN ._. They_PRP had_VBD non-specific_JJ GI_NNP symptoms_NNS like_IN
            diarrhoea_NN and_CC abdominal_NN cramps_NNS without_IN inflammatory_JJ
            bowel_NN disease_NN ._. The_DT histopathology_NN was_VBD negative_JJ for_IN any_DT
            diagnostic_JJ pathology_NN with_IN nonspecific_JJ changes_NNS or_CC normal_JJ
            colonic_JJ mucosa_NN ._.
          
          
            Group_NNP C_NNP
            (_( negative_JJ control_NN II_NNP )_) :_: Included_VBN 21_CD kidney_NN transplant_NN
            patients_NNS (_( 14_CD males_NNS and_CC 7_CD females_NNS ,_, 46_CD to_TO 75_CD years_NNS of_IN
            age_NN ,_, mean_VB 60_CD ._. 3_LS years_NNS )_) with_IN non-specific_JJ GI_NNP symptoms_NNS
            like_IN diarrhea_NN and_CC guaiac_NN positive_JJ stool_NN ._. The_DT sections_NNS
            of_IN colon_NN biopsies_NNS were_VBD histopathologically_RB negative_JJ for_IN
            diagnostic_JJ pathology_NN ._. These_DT patients_NNS in_IN group_NN C_NNP were_VBD
            under_IN maintainance_NN immunosupressive_JJ therapy_NN with_IN
            cyclosporine_NN or_CC tacrolimus_JJ ,_, prednisone_NN ,_, and_CC
            mycophenalate_NN mofetil_NN ._. This_DT group_NN was_VBD included_VBN to_TO study_VB
            if_IN any_DT of_IN the_DT histomorphological_JJ features_NNS evaluted_JJ in_IN
            this_DT study_NN have_VBP significant_JJ relationship_NN with_IN
            transplantation_NN in_IN general_JJ including_VBG effect_NN of_IN
            immunosupressive_JJ therapy_NN ._.
            Subclinical_NNP A-GVHD_NNP in_IN the_DT absence_NN of_IN cutaneous_JJ
            A-GVHD_NNP or_CC gastrointestinal_NN symptoms_NNS is_VBZ known_VBN [_NN 4_CD 10_CD ]_NN ._.
            Because_IN of_IN this_DT reason_NN a_DT fourth_JJ hypothetical_JJ control_NN
            group_NN of_IN biopsies_NNS from_IN BMT_NNP patient_NN without_IN A-GVHD_NNP
            though_IN desired_VBN was_VBD considered_VBN impractical_JJ ,_, as_IN various_JJ
            criteria_NNS under_IN scrutiny_NN in_IN this_DT study_NN will_MD be_VB deciding_VBG
            if_IN those_DT biopsies_NNS would_MD have_VB to_TO be_VB considered_VBN negative_JJ
            for_IN A-GVHD_NNP ._. Other_JJ negative_JJ control_NN group_NN desired_VBN would_MD
            be_VB colonic_JJ biopsies_NNS from_IN the_DT cases_NNS undergoing_VBG all_PDT the_DT
            therapy_NN components_NNS of_IN BMT_NNP including_VBG cytoreductive_JJ
            therapy_NN but_CC without_IN BMT_NNP ._. However_RB ,_, such_JJ a_DT group_NN would_MD
            also_RB be_VB impractical_JJ during_IN any_DT clinical_JJ study_NN due_JJ to_TO
            obvious_JJ ethical_JJ limitations_NNS ._. Autologous_NNP BMT_NNP case_NN
            without_IN cyclosporine_NN induced_VBD GVHD_NNP or_CC viral_JJ infection_NN
            would_MD have_VB been_VBN ideal_JJ control_NN [_NN 28_CD 29_CD ]_NN ._. However_RB ,_, due_JJ
            to_TO limited_JJ number_NN of_IN cases_NNS in_IN this_DT group_NN we_PRP could_MD not_RB
            include_VB such_JJ a_DT group_NN ._.
            Histomorphological_NNP features_NNS secondary_JJ to_TO the_DT effects_NNS
            of_IN non-steroidal_JJ anti-inflammatory_JJ drugs_NNS (_( NSAIDs_NNP )_) [_NN 4_CD 7_CD
            ]_NN and_CC intestinal_NN infections_NNS ,_, especially_RB cytomegalovirus_JJ
            (_( CMV_NNP )_) [_NN 2_CD 9_CD 12_CD 16_CD 17_CD ]_NN are_VBP known_VBN to_TO overlap_VB with_IN
            A-GVHD_NNP ._. Due_JJ to_TO this_DT ,_, based_VBN on_IN clinical_JJ details_NNS ,_, the_DT
            cases_NNS with_IN such_JJ associations_NNS were_VBD excluded_VBN from_IN this_DT
            study_NN ._.
          
        
        
          General_JJ information_NN
          Polyethylene_NNP glycol_NN solution_NN (_( GoLytely_NNP ®_NN ,_, Braintree_NNP
          Laboratories_NNPS ,_, Braintree_NNP ,_, MA_NNP )_) was_VBD used_VBN for_IN endoscopic_JJ
          preparation_NN in_IN all_PDT the_DT groups_NNS ._. Due_JJ to_TO known_VBN subtle_JJ
          differences_NNS between_IN left_VBD and_CC right_JJ side_NN of_IN the_DT colon_NN ,_, the_DT
          proportion_NN of_IN different_JJ sites_NNS in_IN each_DT group_NN was_VBD matched_VBN
          for_IN statistical_JJ correction_NN ._. All_DT colon_NN biopsies_NNS were_VBD fixed_VBN
          in_IN Bouin_NNP 's_POS fixative_JJ and_CC processed_VBN routinely_RB ._. Multiple_NNP
          levels_NNS of_IN paraffin-embedded_JJ tissue_NN sections_NNS stained_JJ with_IN
          H_NNP &_CC E_NNP were_VBD examined_VBN in_IN blinded_JJ fashion_NN without_IN knowing_VBG
          the_DT category_NN ._.
        
        
          Histopathological_NNP Analysis_NNP
          Various_JJ histological_JJ features_NNS important_JJ for_IN the_DT
          differential_NN diagnosis_NN of_IN A-GVHD_NNP were_VBD selected_VBN after_IN
          review_NN of_IN literature_NN [_NN 12_CD 13_CD 14_CD ]_NN ._. All_DT H_NNP &_CC E_NNP stained_JJ
          sections_NNS were_VBD evaluated_VBN qualitatively_RB or_CC
          semi-quantitatively_JJ for_IN histomorphological_JJ features_NNS shown_VBN
          in_IN table_NN 2_CD ._.
          The_DT mucosal_NN thicknesses_NNS (_( Table_NNP 2_CD ,_, A_DT )_) from_IN the_DT surface_NN
          epithelium_NN to_TO the_DT internal_JJ limit_NN of_IN muscularis_NNS mucosa_NN in_IN
          three_CD places_NNS were_VBD measured_VBN in_IN the_DT area_NN of_IN least_JJS thickness_NN
          and_CC mean_VB was_VBD calculated_VBN ._. Thickness_NNP >_NN 500_CD microns_NNS was_VBD
          considered_VBN within_IN normal_JJ limits_NNS [_NN 20_CD ]_NN ._. Cryptitis_NNP and_CC
          crypt_NN abscess_NNS were_VBD defined_VBN respectively_RB as_IN infiltration_NN
          of_IN crypt_NN epithelium_NN with_IN neutrophils_NNS and_CC presence_NN of_IN
          neutrophils_NNS in_IN crypt_NN lumen_NN (_( Table_NNP 2_CD ,_, F_NN )_) ._. Five_CD or_CC fewer_JJR
          intraepithelial_NN lymphocytes_NNS per_IN 100_CD epithelial_NN cells_NNS in_IN
          surface_NN and_CC crypt_NN lining_NN were_VBD considered_VBN to_TO be_VB within_IN
          normal_JJ limits_NNS (_( Table_NNP 2_CD ,_, G_NNP and_CC H_NNP )_) [_NN 21_CD ]_NN ._. We_PRP classified_VBD
          1_CD -_: 5_CD extravascular_NN neutrophils_NNS per_IN 20_CD inflammatory_JJ cells_NNS
          in_IN the_DT lamina_NN propria_NN (_( LP_NNP )_) as_IN mild_JJ increase_NN and_CC more_JJR than_IN
          five_CD as_IN marked_VBN increase_NN (_( Table_NNP 2_CD ,_, L_NNP )_) ._. Macrophages_NNP with_IN
          mucin_NN as_RB faintly_RB basophilic_JJ foamy_NN cytoplasm_NN in_IN H_NNP &_CC E_NNP
          stained_JJ sections_NNS were_VBD identified_VBN as_IN muciphages_NNS ._. Five_CD or_CC
          more_JJR muciphages_NNS in_IN LP_NNP per_IN 10_CD crypts_NNS were_VBD considered_VBN
          significant_JJ (_( Table_NNP 2_CD ,_, P_NN )_) ._. Presence_NNP of_IN five_CD or_CC more_JJR
          endothelial_NN lined_VBD blood_NN spaces_NNS larger_JJR than_IN 50_CD microns_NNS for_IN
          every_DT 10_CD crypts_NNS was_VBD regarded_VBN as_IN increased_VBN microvessel_NN
          network_NN (_( Table_NNP 2_CD ,_, Q_NNP )_) ._. Apoptosis_NNP (_( defined_VBN as_IN single_JJ cell_NN
          death_NN )_) was_VBD indentified_JJ in_IN H_NNP &_CC E_NNP stained_JJ sections_NNS as_IN
          apoptotic_JJ cells_NNS with_IN scattered_VBN karyorrhectic_JJ basophilic_JJ
          globular_NN intracytoplasmic_JJ debris_NN of_IN apoptotic_JJ bodies_NNS
          (_( Figure_NN 1_LS )_) ._. Apoptotic_NNP cells_NNS were_VBD counted_VBN in_IN 10_CD high_JJ power_NN
          field_NN (_( HPF_NNP )_) at_IN 40_CD ×_NN magnification_NN with_IN a_DT field_NN diameter_NN
          of_IN 0_CD ._. 35_CD mm_NN ._. Mitotic_NNP figures_NNS were_VBD counted_VBN per_IN 10_CD crypts_NNS
          (_( Table_NNP 3_LS )_) ._.
        
        
          Statistical_NNP Analysis_NNP
          Each_DT group_NN was_VBD evaluated_VBN for_IN the_DT frequency_NN of_IN various_JJ
          histomorphological_JJ features_NNS shown_VBN in_IN table_NN 2_CD ._. The_DT
          findings_NNS in_IN group_NN A_DT were_VBD compared_VBN with_IN groups_NNS B_NNP and_CC C_NNP
          using_VBG Fisher_NNP 's_POS exact_JJ test_NN (_( Table_NNP 2_LS )_) ._. Number_NNP of_IN apoptotic_JJ
          cells_NNS and_CC mitotic_JJ figures_NNS in_IN group_NN A_DT were_VBD compared_VBN with_IN
          those_DT in_IN groups_NNS B_NNP and_CC C_NNP using_VBG Wilcoxan_NNP Rank_NNP Sum_NNP Test_NNP
          (_( Table_NNP 3_LS )_) ._.
          In_IN order_NN to_TO compensate_VB for_IN the_DT multiple_JJ testing_NN and_CC
          thus_RB to_TO avoid_VB imparting_VBG spurious_JJ significance_NN ,_, we_PRP used_VBD a_DT
          stringent_JJ significance_NN level_NN of_IN 0_CD ._. 002_CD for_IN each_DT test_NN ._. This_DT
          was_VBD based_VBN on_IN the_DT Bonferroni_NNP correction_NN factor_NN for_IN
          multiple_JJ testing_NN to_TO achieve_VB an_DT overall_JJ significance_NN level_NN
          of_IN 5_CD %_NN [_NN 22_CD ]_NN ._. Histomorphological_NNP features_NNS with_IN
          statistically_RB significant_JJ differences_NNS were_VBD separated_JJ for_IN
          further_JJ analysis_NN (_( Table_NNP 4_LS )_) ._.
        
      
      
        Results_NNS
        The_DT comparative_JJ frequency_NN of_IN various_JJ histomorphological_JJ
        features_NNS observed_VBD in_IN all_PDT the_DT three_CD groups_NNS is_VBZ shown_VBN in_IN table_NN
        2_CD ._. Apoptosis_NNP in_IN crypt_NN lining_NN was_VBD associated_VBN with_IN higher_JJR
        frequency_NN in_IN A-GVHD_NNP with_IN statisticaaly_RB significant_JJ
        difference_NN (_( Table_NNP 3_CD and_CC 4_LS )_) ._. Other_JJ features_NNS observed_VBD more_RBR
        often_RB in_IN A-GVHD_NNP with_IN statistically_RB significant_JJ differences_NNS
        as_IN compared_VBN to_TO the_DT negative_JJ control_NN groups_NNS included_VBD (_( Table_NNP
        2_CD and_CC 4_CD ,_, Figure_NN 2_LS )_) :_: pericryptal_NN apoptosis_NNS adjacent_JJ to_TO the_DT
        crypts_NNS in_IN LP_NNP ,_, crypt_NN abnormalities_NNS (_( including_VBG crypt_NN size_NN
        variation_NN ,_, crypt_NN dilatation_NN and_CC irregular_JJ crypt_NN
        distribution_NN )_) ,_, reactive_JJ changes_NNS in_IN LP_NNP (_( including_VBG reduced_VBN
        mucosal_NN thickness_NN ,_, muciphages_NNS in_IN LP_NNP ,_, increased_VBN microvessel_NN
        network_NN ,_, and_CC focal_JJ fibrosis_NNS )_) ,_, and_CC reactive_JJ changes_NNS in_IN the_DT
        surface_NN epithelium_NN with_IN mucin_NN depletion_NN ._.
        Apoptosis_NNP in_IN crypt_NN lining_NN was_VBD observed_VBN in_IN 91_CD %_NN of_IN group_NN A_DT
        cases_NNS with_IN A-GVHD_NNP and_CC demonstrated_VBN statistically_RB
        significant_JJ difference_NN as_IN compared_VBN to_TO negative_JJ control_NN
        group_NN B_NNP and_CC C_NNP (_( p_NN <_NN 0_CD ._. 002_CD ,_, Fisher_NNP 's_POS exact_JJ test_NN )_) (_( Table_NNP 2_CD K_NNP
        
        2_LS ,_, Figure_NN 1_LS )_) ._. In_IN group_NN A_DT ,_, 70_CD %_NN of_IN cases_NNS
        showed_VBD apoptotic_JJ cells_NNS in_IN LP_NNP around_IN the_DT crypts_NNS as_IN compared_VBN
        to_TO 22_CD %_NN in_IN group_NN B_NNP and_CC 5_CD %_NN in_IN group_NN C_NNP (_( p_NN <_NN 0_CD ._. 002_CD )_) (_( Table_NNP
        2_CD K_NNP 
        4_LS )_) ._. Apoptosis_NNP in_IN the_DT surface_NN epithelium_NN
        did_VBD not_RB show_VB any_DT significant_JJ difference_NN between_IN the_DT three_CD
        groups_NNS (_( Table_NNP 2_CD K_NNP 
        1_LS )_) ._. Apoptotic_NNP bodies_NNS in_IN LP_NNP adjacent_JJ to_TO
        the_DT surface_NN epithelium_NN were_VBD also_RB non-specific_JJ and_CC did_VBD not_RB
        show_VB significant_JJ difference_NN between_IN the_DT three_CD groups_NNS (_( Table_NNP
        2_CD K_NNP 
        3_LS )_) ._. An_DT average_JJ 5_CD ._. 3_CD apoptotic_JJ cells_NNS per_IN
        10_CD HPF_NNP were_VBD observed_VBN in_IN group_NN A_DT ,_, in_IN contrast_NN to_TO only_RB 1_CD ._. 25_CD
        in_IN group_NN B_NNP and_CC 1_CD ._. 42_CD in_IN group_NN C_NNP (_( p_NN <_NN 0_CD ._. 002_CD ,_, Wilcoxan_NNP Rank_NNP
        Sum_NNP Test_NNP )_) (_( Table_NNP 3_LS )_) ._.
        Intraepithelial_NNP lymphocytes_NNS and_CC neutrophils_NNS in_IN the_DT
        surface_NN epithelium_NN and_CC the_DT crypt_NN epithelium_NN did_VBD not_RB show_VB
        statistically_RB significant_JJ difference_NN in_IN A-GVHD_NNP group_NN and_CC
        negative_JJ controls_NNS (_( Table_NNP 2_CD ,_, G_NNP ,_, H_NNP ,_, I_PRP ,_, J_NNP )_) ._. Neutrophils_NNP ,_,
        eosinophils_NNS ,_, and_CC edema_NN in_IN LP_NNP were_VBD nonspecific_JJ and_CC were_VBD
        observed_VBN with_IN comparable_JJ frequencies_NNS in_IN all_PDT the_DT three_CD
        categories_NNS (_( Table_NNP 2_CD ,_, L_NNP ,_, M_NNP ,_, O_NNP )_) ._. The_DT number_NN of_IN mitotic_JJ figures_NNS
        in_IN crypt_NN lining_NN did_VBD not_RB show_VB statistically_RB significant_JJ
        difference_NN between_IN the_DT three_CD groups_NNS (_( Table_NNP 3_LS )_) ._.
      
      
        Discussion_NNP
        Some_DT of_IN the_DT histological_JJ features_NNS of_IN A-GVHD_NNP in_IN colonic_JJ
        biopsies_NNS have_VBP been_VBN studied_VBN and_CC reported_VBN previously_RB [_NN 6_CD 11_CD
        14_CD 23_CD ]_NN ._. But_CC they_PRP have_VBP not_RB been_VBN evaluated_VBN together_RB as_IN
        collective_JJ features_NNS with_IN methodical_JJ statistical_JJ analysis_NN ._.
        Crypt_NNP cell_NN apoptosis_NNS has_VBZ been_VBN described_VBN as_IN a_DT significant_JJ
        finding_NN in_IN intestinal_NN A-GVHD_NNP ._. Usually_RB this_DT is_VBZ focal_JJ in_IN
        nature_NN and_CC results_NNS in_IN membrane_NN bound_VBN debris_NN of_IN apoptotic_JJ
        bodies_NNS in_IN the_DT crypts_NNS ._. This_DT phenomenon_NN has_VBZ been_VBN labeled_VBN
        variously_RB as_IN "_'' exploding_VBG crypt_NN cells_NNS "_'' [_NN 13_CD 24_CD ]_NN ,_,
        "_'' karyolytic_JJ body_NN [_NN 1_CD 12_CD 14_CD ]_NN ,_, "_'' apoptotic_JJ body_NN "_'' [_NN 1_CD 12_CD ]_NN ,_,
        "_'' granular_JJ necrosis_NNS "_'' ,_, [_NN 2_CD ]_NN and_CC "_'' popcorn_NN lesions_NNS "_'' [_NN 2_CD 13_CD ]_NN
        (_( Figure_NN 1_LS )_) ._. Though_IN this_DT lesion_NN is_VBZ not_RB specific_JJ for_IN A-GVHD_NNP ,_,
        it_PRP is_VBZ a_DT cardinal_NN feature_NN as_IN demonstrated_VBN by_IN experimental_JJ
        production_NN of_IN intestinal_NN A-GVHD_NNP in_IN the_DT Rhesus_NNP monkey_NN [_NN 14_CD
        25_CD ]_NN ._. It_PRP is_VBZ a_DT valuable_JJ diagnostic_JJ feature_NN in_IN the_DT absence_NN
        of_IN infections_NNS especially_RB CMV_NNP [_NN 2_CD 4_CD 7_CD 9_CD 12_CD 16_CD 17_CD ]_NN ._. Other_JJ
        critical_JJ differential_NN diagnoses_NNS include_VBP effects_NNS of_IN
        radiation-chemotherapy_JJ [_NN 12_CD 13_CD ]_NN and_CC effects_NNS of_IN other_JJ drugs_NNS
        such_JJ as_IN NSAIDs_NNP [_NN 7_CD ]_NN ._.
        A_DT higher_JJR number_NN of_IN apoptotic_JJ bodies_NNS were_VBD observed_VBN in_IN
        A-GVHD_NNP than_IN in_IN negative_JJ controls_NNS (_( Table_NNP 3_LS )_) ._. The_DT
        distribution_NN pattern_NN of_IN apoptosis_NNS in_IN colon_NN biopsies_NNS with_IN
        A-GVHD_NNP has_VBZ not_RB been_VBN evaluated_VBN previously_RB with_IN statistical_JJ
        analysis_NN ._. In_IN this_DT study_NN ,_, a_DT statistically_RB significant_JJ
        difference_NN was_VBD noted_VBN when_WRB the_DT distribution_NN of_IN apoptotic_JJ
        bodies_NNS in_IN crypts_NNS and_CC around_IN the_DT crypts_NNS was_VBD compared_VBN with_IN
        those_DT in_IN surface_NN epithelium_NN and_CC adjacent_JJ to_TO the_DT surface_NN
        epithelium_NN ._.
        The_DT frequency_NN of_IN apoptotic_JJ bodies_NNS in_IN surface_NN epithelium_NN
        and_CC adjacent_JJ LP_NNP in_IN all_PDT the_DT three_CD groups_NNS were_VBD comparable_JJ and_CC
        did_VBD not_RB show_VB statistically_RB significant_JJ difference_NN (_( Table_NNP 2_CD ,_,
        K_NNP 
        1_CD and_CC K_NNP 
        3_LS )_) ._. The_DT presence_NN of_IN apoptosis_NNS in_IN
        surface_NN epithelium_NN or_CC in_IN adjacent_JJ LP_NNP is_VBZ nonspecific_JJ ._. In_IN the_DT
        absence_NN of_IN apoptosis_NNS in_IN the_DT crypts_NNS ,_, presence_NN of_IN apoptosis_NNS
        along_IN the_DT surface_NN epithelium_NN does_VBZ not_RB have_VB any_DT diagnostic_JJ
        significance_NN for_IN A-GVHD_NNP ._. The_DT cause_NN of_IN apoptosis_NNS along_IN the_DT
        surface_NN epithelium_NN is_VBZ physiological_JJ turnover_NN with_IN loss_NN from_IN
        the_DT surface_NN epithelium_NN and_CC the_DT replacement_NN by_IN proliferation_NN
        of_IN cells_NNS in_IN the_DT crypts_NNS ._. Variety_NNP of_IN non-specific_JJ factors_NNS may_MD
        accelerate_VB this_DT with_IN increased_VBN number_NN of_IN apoptotic_JJ cells_NNS
        along_IN the_DT surface_NN epithelium_NN ._.
        As_IN compared_VBN to_TO the_DT negative_JJ controls_NNS (_( group_NN B-_NNP 11_CD %_NN and_CC
        group_NN C-_NNP 14_CD %_NN )_) ,_, crypt_NN apoptosis_NNS was_VBD frequent_JJ in_IN A-GVHD-_NNP 91_CD %_NN
        with_IN statistically_RB significant_JJ difference_NN (_( Table_NNP 2_CD K_NNP 
        2_LS )_) ._. With_IN proper_JJ clinical_JJ history_NN ,_, the_DT
        diagnosis_NN of_IN A-GVHD_NNP can_MD be_VB suggested_VBN if_IN apoptosis_NNS is_VBZ
        observed_VBN in_IN and_CC around_IN the_DT crypts_NNS ._. Association_NNP of_IN cryptal_NN
        apoptosis_NNS with_IN other_JJ features_NNS (_( Table_NNP 4_LS )_) should_MD increase_VB the_DT
        diagnostic_JJ accuracy_NN ._. These_DT associations_NNS included_VBD reactive_JJ
        changes_NNS in_IN the_DT surface_NN epithelium_NN ,_, increased_VBN muciphages_NNS ,_,
        reduced_VBN mucosal_NN thickness_NN ,_, focal_JJ fibrosis_NNS in_IN LP_NNP ,_, irregular_JJ
        distribution_NN of_IN crypts_NNS ,_, crypt_NN dilatation_NN ,_, and_CC crypt_NN size_NN
        variation_NN (_( Table_NNP 4_LS )_) ._. However_RB ,_, some_DT of_IN these_DT features_NNS may_MD be_VB
        secondary_JJ to_TO cytoreductive_JJ therapy_NN and_CC other_JJ components_NNS of_IN
        BMT_NNP ._. In_IN general_JJ ,_, the_DT effects_NNS of_IN cytoreductive_JJ therapy_NN are_VBP
        not_RB observed_VBN after_IN 20_CD days_NNS [_NN 12_CD ]_NN ._. Under_IN proper_JJ clinical_JJ
        situation_NN ,_, their_PRP$ association_NN with_IN apoptosis_NNS in_IN crypts_NNS and_CC
        pericryptal_NN apoptosis_NNS in_IN LP_NNP is_VBZ consistent_JJ with_IN A-GVHD_NNP in_IN
        BMT_NNP ._. Further_RB evaluation_NN of_IN these_DT features_NNS in_IN relation_NN to_TO
        individual_JJ components_NNS of_IN BMT_NNP protocols_NNS may_MD be_VB conducted_VBN as_IN
        animal_NN experiments_NNS with_IN proper_JJ controls_NNS ._. As_IN mentioned_VBN under_IN
        materials_NNS and_CC methods_NNS ,_, such_JJ evaluation_NN would_MD be_VB impractical_JJ
        as_IN clinical_JJ study_NN due_JJ to_TO obvious_JJ ethical_JJ limitations_NNS in_IN
        organizing_VBG proper_JJ controls_NNS ._.
        Patients_NNS with_IN cutaneous_JJ and_CC hepatic_JJ A-GVHD_NNP frequently_RB
        have_VBP apoptosis_NNS in_IN their_PRP$ colon_NN biopsies_NNS ,_, without_IN any_DT
        intestinal_NN symptoms_NNS [_NN 4_CD ]_NN ._. This_DT may_MD represent_VB sub-clinical_JJ
        intestinal_NN A-GVHD_NNP if_IN the_DT apoptosis_NNS is_VBZ observed_VBN in_IN relation_NN
        to_TO the_DT crypts_NNS [_NN 10_CD ]_NN ._. If_IN other_JJ findings_NNS (_( Table_NNP 4_LS )_) are_VBP
        present_JJ in_IN the_DT absence_NN of_IN crypt_NN apoptosis_NNS ,_, it_PRP may_MD represent_VB
        evidence_NN of_IN past_JJ A-GVHD_NNP or_CC due_JJ to_TO other_JJ etiologic_JJ factors_NNS
        such_JJ as_IN chronic_JJ infections_NNS and_CC inflammatory_JJ bowel_NN
        disease_NN ._.
        As_IN noted_VBD in_IN this_DT study_NN ,_, classical_JJ cryptitis_NNS with_IN
        infiltration_NN of_IN crypt-lining_JJ by_IN neutrophils_NNS and_CC crypt_NN
        abscesses_NNS with_IN neutrophils_NNS within_IN crypt_NN lumens_NNS observed_VBD in_IN
        inflammatory_JJ bowel_NN disease_NN were_VBD not_RB features_VBZ of_IN intestinal_NN
        A-GVHD_NNP (_( Table_NNP 2_CD ,_, F_NN )_) ._. '_POS Cryptitis_NNP '_POS has_VBZ been_VBN described_VBN in_IN
        association_NN with_IN A-GVHD_NNP ,_, but_CC these_DT studies_NNS do_VBP not_RB define_VB
        the_DT term_NN [_NN 6_CD 12_CD 13_CD ]_NN ._. Although_IN reference_NN had_VBD been_VBN made_VBN to_TO
        crypt_NN abscesses_NNS in_IN these_DT reports_NNS ,_, it_PRP is_VBZ evident_JJ that_IN the_DT
        researchers_NNS were_VBD looking_VBG at_IN the_DT apoptotic_JJ debris_NN in_IN gland_NN
        lumina_NN and_CC suggested_VBD '_POS crypt_NN abscess-like_JJ '_POS changes_NNS [_NN 14_CD ]_NN ._.
        In_IN our_PRP$ study_NN ,_, only_RB one_CD case_NN (_( 2_CD ._. 7_CD %_NN )_) from_IN group_NN A_DT with_IN A-GVHD_NNP
        showed_VBD occasional_JJ crypt_NN abscess_NNS (_( Table_NNP 2_LS )_) and_CC this_DT may_MD
        represent_VB a_DT coincidental_JJ inflammatory_JJ bowel_NN disease_NN -_: like_IN
        damage_NN [_NN 26_CD ]_NN ._. Mild_NNP cryptitis_NNS with_IN a_DT few_JJ crypt_NN abscesses_NNS
        was_VBD also_RB observed_VBN in_IN one_CD patient_NN (_( 4_CD ._. 76_CD %_NN )_) in_IN group_NN C_NNP with_IN
        kidney_NN transplantation_NN (_( Table_NNP 2_LS )_) ._. Thus_RB ,_, classical_JJ cryptitis_NNS
        and_CC crypt_NN abscesses_NNS with_IN infiltration_NN of_IN crypt_NN lining_NN and_CC
        crypt_NN lumen_NN with_IN neutrophils_NNS observed_VBD in_IN inflammatory_JJ bowel_NN
        disease_NN is_VBZ not_RB a_DT feature_NN of_IN A-GVHD_NNP ._.
        A_DT change_NN ,_, that_WDT was_VBD called_VBN focal_JJ periglandular_NN infiltrate_VB
        by_IN Bombi_NNP et_CC al_NN [_NN 6_CD ]_NN ,_, was_VBD observed_VBN by_IN us_PRP in_IN three_CD (_( 6_CD ._. 9_CD %_NN )_)
        cases_NNS of_IN A-GVHD_NNP involving_VBG only_RB one_CD or_CC two_CD crypts_NNS (_( Table_NNP 2_CD ,_,
        N_NNP )_) ._. Sale_NN and_CC colleagues_NNS described_VBD a_DT comparable_JJ feature_NN with_IN
        "_'' focal_JJ increase_NN in_IN density_NN of_IN lymphocytes_NNS ,_, plasma_NN cells_NNS ,_,
        and_CC occasional_JJ eosinophils_NNS in_IN the_DT LP_NNP "_'' [_NN 13_CD ]_NN ._. This_DT finding_VBG
        was_VBD suggested_VBN as_IN a_DT marker_NN for_IN apoptosis_NNS favoring_VBG the_DT
        clinical_JJ diagnosis_NN of_IN A-GVHD_NNP [_NN 6_CD ]_NN ._. They_PRP have_VBP suggested_VBN
        that_IN the_DT presence_NN of_IN focal_JJ periglandular_NN infiltrate_VB
        warrants_VBZ a_DT careful_JJ search_NN for_IN cryptal_NN apoptosis_NNS ._. We_PRP did_VBD not_RB
        observe_VB this_DT finding_VBG in_IN negative_JJ control_NN groups_NNS B_NNP and_CC
        C_NNP ._.
        The_DT clusters_NNS of_IN enterochromaffin_NN cells_NNS in_IN A-GVHD_NNP have_VBP
        been_VBN reported_VBN previously_RB [_NN 25_CD 27_CD ]_NN ._. They_PRP have_VBP been_VBN
        described_VBN in_IN association_NN with_IN apoptosis_NNS ,_, suggesting_VBG their_PRP$
        presence_NN as_IN the_DT result_NN of_IN selective_JJ sparing_VBG of_IN
        enterochromaffin_NN elements_NNS during_IN the_DT process_NN of_IN A-GVHD_NNP ._. We_PRP
        did_VBD not_RB observe_VB them_PRP in_IN H_NNP &_CC E_NNP stained_JJ sections_NNS (_( Table_NNP 2_CD ,_,
        R_NN )_) ._.
      
      
        Conclusions_NNP
        Apoptosis_NNP in_IN crypt_NN lining_NN and_CC pericryptal_NN apoptosis_NNS
        adjacent_JJ to_TO crypts_NNS in_IN LP_NNP ,_, especially_RB when_WRB associated_VBN with_IN
        the_DT features_NNS such_JJ as_IN crypt_NN abnormalities_NNS and_CC reactive_JJ
        changes_NNS in_IN mucosa_NN (_( LP_NNP and_CC surface_NN epithelium_NN )_) favor_NN the_DT
        diagnosis_NN of_IN A-GVHD_NNP ._. Cryptitis_NNP and_CC crypt_NN abscesses_NNS are_VBP not_RB
        feature_VB of_IN A-GVHD_NNP and_CC should_MD be_VB differentiated_JJ from_IN
        "_'' popcorn_NN lesions_NNS "_'' ,_, which_WDT show_VBP apoptotic_JJ cells_NNS instead_RB of_IN
        neutrophils_NNS along_IN the_DT crypt_NN lining_NN and_CC in_IN the_DT crypt_NN
        lumen_NN ._.
      
      
        List_NN of_IN abbreviations_NNS
        A-GVHD_NNP ,_, Acute_NNP graft-versus-host_JJ disease_NN ;_: BMT_NNP ,_, bone_NN
        marrow_NN transplantation_NN ;_: LP_NNP ,_, lamina_NN propria_NN ;_: H_NNP &_CC E_NNP ,_,
        hematoxylin_NN and_CC eosin_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        VS_NNP conceived_VBD ,_, designed_VBN ,_, and_CC carried_VBD out_RP the_DT entire_JJ study_NN
        in_IN addition_NN to_TO the_DT drafting_VBG of_IN manuscript_NN ._. CC_NNP participated_VBD
        in_IN the_DT design_NN of_IN the_DT study_NN and_CC performed_VBD the_DT statistical_JJ
        analysis_NN ._. GB_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC
        contributed_VBD data_NNS on_IN negative_JJ controls_NNS in_IN kidney_NN transplant_NN
        group_NN ._. FG_NNP participated_VBD in_IN the_DT design_NN of_IN the_DT study_NN and_CC
        assisted_VBN in_IN data_NNS collection_NN ._. PF_NNP ,_, BK_NNP ,_, and_CC RK_NNP all_DT
        participated_VBD in_IN its_PRP$ design_NN and_CC coordination_NN ._. VG_NNP performed_VBD
        the_DT statistical_JJ analysis_NN ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT
        final_JJ manuscript_NN ._.
      
    
  
